This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kirchhof, P. F. Articles by Franz, M. R. Search for Related Content PubMed PubMed Citation Articles by Kirchhof, P. F. Articles by Franz, M. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Arrhythmia Hazardous Substances DB PROCAINAMIDE

(Circulation. 1998;97:2567-2574.)
© 1998 American Heart Association, Inc.

Basic Science Reports

Postrepolarization Refractoriness Versus Conduction Slowing Caused by Class I Antiarrhythmic Drugs

Antiarrhythmic and Proarrhythmic Effects

Paulus F. Kirchhof, MD; C. Larissa Fabritz, MD; ; Michael R. Franz, MD, PhD

From the Cardiology Divisions, Veterans National Administration and Georgetown University Medical Centers, Washington, DC (P.F.K., C.L.F., M.R.F.) and the University of Münster, Germany (P.F.K., C.L.F.).

Correspondence to Michael R. Franz, MD, PhD, Veterans Administration Medical Center, 50 Irving St, NW, Washington, DC 20422.

Background—Conduction block may be both antiarrhythmic and proarrhythmic. Drug-induced postrepolarization refractoriness (PRR) may prevent premature excitation and tachyarrhythmia induction. The effects of propafenone and procainamide on these parameters, and their antiarrhythmic or proarrhythmic consequences, were investigated.

Methods and Results—In 11 isolated Langendorff-perfused rabbit hearts, monophasic action potentials (MAPs) were recorded simultaneously from six to seven different right and left ventricular sites, along with a volume-conducted ECG. All recordings were used to discern ventricular tachycardia (VT) or ventricular fibrillation (VF) induced by repetitive extrastimulation (S2-S5) or 10-second burst stimulation at 25 to 200 Hz at baseline and after addition of procainamide (20 µmol/L) or propafenone (1 µmol/L) to the perfusate. MAPs were analyzed for action potential duration at 90% repolarization (APD₉₀), conduction times (CT) between the pacing site and the other MAPs, and PRR (effective refractory period-APD₉₀=PRR) and related to the induction of VT or VF. During steady-state pacing, procainamide and propafenone prolonged APD₉₀ by 12% and 14%, respectively. Procainamide slowed mean CT by 40% during S2-S5 pacing, whereas propafenone slowed mean CT by up to 400% (P<0.001 versus baseline and procainamide). Wavelength was not changed significantly by procainamide but was shortened fourfold by propafenone at S5. Both drugs produced PRR, which was associated with a 70% decrease in VF inducibility with procainamide and elimination of VF with propafenone. Despite this protection from VF, monomorphic VT was induced with propafenone in 57% of burst stimulations.

Conclusions—Drug-induced PRR protects against VF induction. Propafenone promotes slow monomorphic VT, probably by use-dependent conduction slowing and wavelength shortening.

Key Words: fibrillation • conduction • propafenone • procainamide

This article has been cited by other articles:

				P. Kirchhof, H. Degen, M. R. Franz, L. Eckardt, L. Fabritz, P. Milberg, S. Laer, J. Neumann, G. Breithardt, and W. Haverkamp Amiodarone-Induced Postrepolarization Refractoriness Suppresses Induction of Ventricular Fibrillation J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 257 - 263. [Abstract] [Full Text]

				L. Fabritz, P. Kirchhof, M. R Franz, D. Nuyens, T. Rossenbacker, A. Ottenhof, W. Haverkamp, G. Breithardt, E. Carmeliet, and P. Carmeliet Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in {Delta}KPQ SCN5A (long QT3) mice Cardiovasc Res, March 15, 2003; 57(4): 1085 - 1093. [Abstract] [Full Text] [PDF]

				J. Huang, J. L. Skinner, J. M. Rogers, W. M. Smith, W. L. Holman, and R. E. Ideker The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogs J. Am. Coll. Cardiol., July 17, 2002; 40(2): 375 - 383. [Abstract] [Full Text] [PDF]

				A. N Plotnikov, A. Shvilkin, W. Xiong, J. R de Groot, L. Rosenshtraukh, S. Feinmark, R. Gainullin, P. Danilo Jr., and M. R Rosen Interactions between antiarrhythmic drugs and cardiac memory Cardiovasc Res, May 1, 2001; 50(2): 335 - 344. [Abstract] [Full Text] [PDF]

				M. Valderrabano and B. N. Singh Review : Electrophysiologic and Antiarrhythmic Effects of Propafenone: Focus on Atrial Fibrillation Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1999; 4(3): 183 - 198. [PDF]